menu
    • menu

    Find Clofazimine manufacturers, exporters & distributors on PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    10

    API Suppliers

    API Suppliers

    8

    USDMF

    US DMFs Filed

    3

    CEP/COS

    CEP/COS Certifications

    1

    JDMF

    JDMFs Filed

    1

    EU WC

    EU WC

    0

    KDMF

    KDMF

    3

    NDC API

    NDC API

    0

    VMF

    NDC API

    3

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 631

    MARKET PLACE

    9

    API

    5

    FDF

    1INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    3

    FDF Dossiers

    FDF Dossiers

    2

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    1

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    18DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    1

    EDQM

    2

    USP

    0

    JP

    2

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    1

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    7

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Finished Drug Prices

    NA

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 2030-63-9, Lamprene, Chlofazimine, Lampren, Clofazimina, Clofaziminum
    Molecular Formula
    C27H22Cl2N4
    Molecular Weight
    473.4  g/mol
    InChI Key
    WDQPAMHFFCXSNU-UHFFFAOYSA-N
    FDA UNII
    D959AE5USF
    Clofazimine
    A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
    Clofazimine is an Antimycobacterial.
    1 2D Structure

    Clofazimine

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine
    2.1.2 InChI
    InChI=1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3
    2.1.3 InChI Key
    WDQPAMHFFCXSNU-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl
    2.2 Other Identifiers
    2.2.1 UNII
    D959AE5USF
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. B 663

    2. B-663

    3. B663

    4. G 30,320

    5. G-30,320

    6. G30,320

    7. Lamprene

    8. N,5-bis(4-chlorophenyl)-3,5-dihydro-3-((1-methylethyl)imino)-2-phenazinamine

    2.3.2 Depositor-Supplied Synonyms

    1. 2030-63-9

    2. Lamprene

    3. Chlofazimine

    4. Lampren

    5. Clofazimina

    6. Clofaziminum

    7. Nsc-141046

    8. B 663 (pharmaceutical)

    9. Clofaziminum [inn-latin]

    10. Clofazimina [inn-spanish]

    11. G 30320

    12. N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine

    13. B-663

    14. 3-(p-chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin

    15. 3-(p-chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine

    16. B 663

    17. 3-(p-chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine

    18. G-30320

    19. D959ae5usf

    20. 2-phenazinamine, N,5-bis(4-chlorophenyl)-3,5-dihydro-3-((1-methylethyl)imino)-

    21. Chembl1083384

    22. N,5-bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine

    23. 2-phenazinamine, 3,5-dihydro-n,5-bis(4-chlorophenyl)-3-((1-methylethyl)imino)-

    24. N,5-bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine

    25. Mmv687800

    26. Nsc141046

    27. Phenazine, 2,10-dihydro-3-(p-chloroanilino)-10-(p-chlorophenyl)-2-(isopropylimino)-

    28. Phenazine, 3-(p-chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-

    29. Ncgc00016600-01

    30. Cas-2030-63-9

    31. N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine

    32. 2-phenazinamine, N,5-bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-

    33. 3-(p-chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine

    34. Riminophenazine

    35. (e)-n,5-bis(4-chlorophenyl)-3-(isopropylimino)-3,5-dihydrophenazin-2-amine

    36. N,5-bis(4-chlorophenyl)-3,5-dihydro-3-(isopropyliaino)phenazin-2-amine

    37. B 663 (van)

    38. (3z)-n,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine

    39. Lamprene (tn)

    40. Smr000058704

    41. B 663, Pharmaceutical

    42. Sr-05000001807

    43. Einecs 217-980-2

    44. Unii-d959ae5usf

    45. Nsc 141046

    46. Brn 0060420

    47. Colfazimine

    48. Clofazimine (jan/usp/inn)

    49. (3e)-n,5-bis(4-chlorophenyl)-3-isopropylimino-phenazin-2-amine

    50. Liposome-encapsulated Clofazimine

    51. Clofazimine [usan:usp:inn:ban]

    52. Prestwick_685

    53. Mfcd00056793

    54. 3-(p-chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [german]

    55. Smp2_000339

    56. (non-d)clofazimine-d7

    57. B663

    58. Cpd000058704

    59. Clofazimine [mi]

    60. Prestwick0_000376

    61. Prestwick1_000376

    62. Prestwick2_000376

    63. Prestwick3_000376

    64. Clofazimine [inn]

    65. Clofazimine [jan]

    66. Dsstox_cid_2839

    67. Clofazimine [usan]

    68. B. 663

    69. Clofazimine [vandf]

    70. Colfazimine [vandf]

    71. Cid_2794

    72. Chembl1292

    73. Clofazimine [mart.]

    74. Dsstox_rid_76752

    75. Bidd:pxr0147

    76. Dsstox_gsid_22839

    77. Schembl26757

    78. Schembl26758

    79. Bspbio_000531

    80. Clofazimine [usp-rs]

    81. Clofazimine [who-dd]

    82. Clofazimine [who-ip]

    83. 4-25-00-03033 (beilstein Handbook Reference)

    84. Mls000028617

    85. Mls001424318

    86. Mls006010789

    87. Spbio_002452

    88. Bpbio1_000585

    89. Chebi:3749

    90. Gtpl9184

    91. Schembl5663361

    92. Dtxsid7022839

    93. Clofazimine [orange Book]

    94. Clofazimine [ep Monograph]

    95. Clofazimine [usp Impurity]

    96. Hms1569k13

    97. Hms2052b05

    98. Hms2093j10

    99. Hms2096k13

    100. Hms2231b04

    101. Hms3370n05

    102. Hms3394b05

    103. Hms3652a16

    104. Hms3713k13

    105. Kuc109573n

    106. Pharmakon1600-01505974

    107. Clofazimine [usp Monograph]

    108. Amy22515

    109. Bcp07792

    110. Clofaziminum [who-ip Latin]

    111. Hy-b1046

    112. Ksc-27-052a

    113. Tox21_110516

    114. Bdbm50318909

    115. Bdbm50378783

    116. Nsc759283

    117. S4107

    118. Zinc17953024

    119. Akos015896438

    120. Akos026749881

    121. Zinc100037101

    122. Zinc253916263

    123. Ccg-101159

    124. Ccg-269477

    125. Cs-4567

    126. Db00845

    127. Ks-1412

    128. Nc00409

    129. Nsc-759283

    130. Ncgc00016600-02

    131. Ncgc00016600-03

    132. Ncgc00016600-04

    133. Ncgc00016600-05

    134. Ncgc00016600-07

    135. Ncgc00016600-08

    136. Ncgc00016600-09

    137. Ncgc00179529-01

    138. Smr004701474

    139. Clofazimine 100 Microg/ml In Acetonitrile

    140. Phenazine,10-dihydro-2-(isopropylimino)-

    141. Sbi-0206865.p001

    142. Ft-0657414

    143. Sw196840-4

    144. A16462

    145. C06915

    146. D00278

    147. 030c639

    148. A814428

    149. Q418611

    150. Sr-01000000259

    151. J-013203

    152. Sr-01000000259-6

    153. Sr-05000001807-1

    154. Sr-05000001807-2

    155. Brd-k56614220-001-10-9

    156. Z2037279473

    157. Clofazimine, European Pharmacopoeia (ep) Reference Standard

    158. N,5-bis(4-chlorophenyl)-3-propan-2-ylimino-2-phenazinamine

    159. N,5-bis(4-chlorophenyl)-3-propan-2-ylimino-phenazin-2-amine

    160. Clofazimine, United States Pharmacopeia (usp) Reference Standard

    161. 2-p-chloranilino-5-p-chlorphenyl-3,5-dihydro-3-isopropylimino-phenazin

    162. N,5-bis(4-chlorophenyl)-3-(isopropylimino)-3,5-dihydrophenazin-2-amine

    163. (4-chloro-phenyl)-[5-(4-chloro-phenyl)-3-isopropylimino-3,5-dihydro-phenazin-2-yl]-amine

    164. 2-phenazinamine,5-bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-

    165. 2-phenazinamine,5-dihydro-n,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-

    166. 2-phenazinamine,n,5-bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-

    167. Clofazimine For System Suitability, European Pharmacopoeia (ep) Reference Standard

    168. N,5-bis(4-chlorophenyl)-3-([1-methylethyl]imino)-3,5-dihydro-2-phenazinamine #

    169. N,5-bis(4-chlorophenyl)-3-[(propan-2-yl)imino]-3,5-dihydrophenazin-2-amine

    170. Phenazine,10-dihydro-3-(p-chloroanilino)-10-(p-chlorophenyl)-2-(isopropylimino)-

    2.4 Create Date
    2005-03-25
    3 Chemical and Physical Properties
    Molecular Weight 473.4 g/mol
    Molecular Formula C27H22Cl2N4
    XLogP37.1
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count4
    Rotatable Bond Count4
    Exact Mass472.1221521 g/mol
    Monoisotopic Mass472.1221521 g/mol
    Topological Polar Surface Area40 Ų
    Heavy Atom Count33
    Formal Charge0
    Complexity829
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameLamprene
    PubMed HealthClofazimine (By mouth)
    Drug ClassesLeprostatic
    Active IngredientClofazimine
    Dosage FormCapsule
    RouteOral
    Strength50mg
    Market StatusPrescription
    CompanyNovartis

    2 of 2  
    Drug NameLamprene
    PubMed HealthClofazimine (By mouth)
    Drug ClassesLeprostatic
    Active IngredientClofazimine
    Dosage FormCapsule
    RouteOral
    Strength50mg
    Market StatusPrescription
    CompanyNovartis

    4.2 Drug Indication

    Clofazimine is indicated for the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum. To prevent the development of drug resistance, it should be used only in combination with other antimycobacterial leprosy treatments.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Clofazimine exerts a slow bactericidal effect on Mycobacterium leprae (Hansen's bacillus) due primarily to its action on the bacterial outer membrane, though there is some evidence that activity on the bacterial respiratory chain and ion transporters may play a role. It also exerts anti-inflammatory properties due to the suppression of T-lymphocyte activity. Clofazimine has a relatively long duration of action owing to its long residence time in the body, but is still administered daily. Approximately 75-100% of patients receiving clofazimine will experience an orange-pink to brownish-black discoloration of the skin, conjunctivae, and bodily fluids. Skin discoloration may take several months or years to reverse following the cessation of therapy. Clofazimine has also been implicated in abdominal obstruction, in some cases fatal, due to the deposition of drug and formation of crystals in the intestinal mucosa - complaints of abdominal pain and nausea/vomiting should be investigated promptly, and the doses of clofazimine should be lowered or discontinued if it is found to be the culprit. Its use should be avoided in patients with hepatic dysfunction.

    5.2 MeSH Pharmacological Classification

    Leprostatic Agents

    Substances that suppress Mycobacterium leprae, ameliorate the clinical manifestations of leprosy, and/or reduce the incidence and severity of leprous reactions. (See all compounds classified as Leprostatic Agents.)

    Anti-Inflammatory Agents

    Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    CLOFAZIMINE
    5.3.2 FDA UNII
    D959AE5USF
    5.3.3 Pharmacological Classes
    Established Pharmacologic Class [EPC] - Antimycobacterial
    5.4 ATC Code

    J - Antiinfectives for systemic use

    J04 - Antimycobacterials

    J04B - Drugs for treatment of lepra

    J04BA - Drugs for treatment of lepra

    J04BA01 - Clofazimine

    5.5 Absorption, Distribution and Excretion

    Absorption

    Absorption varies from 45 to 62% following oral administration in leprosy patients. Co-administration of a 200mg dose of clofazimine with food resulted in a Cmax of 0.41 mg/L with a Tmax of 8 h; administered in a fasting state, the corresponding Cmax was 30% lower while the time to Cmax was 12 h.

    Route of Elimination

    Part of an ingested dose of clofazimine is found in the feces, which may represent excretion in the bile, and a small amount is also eliminated in the sputum, sebum, and sweat. Excretion of unchanged drug and metabolites in a 24-hour urine collection was negligible.

    Volume of Distribution

    Clofazimine is highly lipophilic and therefore deposits primarily in fatty tissues and cells of the reticuloendothelial system, where it is taken up by macrophages and further distributed throughout the body. Crystalized deposits have been found in the mesenteric lymph nodes, adrenals, subcutaneous fat, liver, bile, gall bladder, spleen, small intestine, muscles, bones, and skin.

    5.6 Metabolism/Metabolites

    Three metabolites have been identified in the urine following repeated oral doses of clofazimine. It is unclear whether these metabolites are pharmacologically active. Metabolite I may be the result of the hydrolytic dehalogenation of clofazimine and metabolite II presumably is formed by a hydrolytic deamination reaction followed by glucuronidation.

    5.7 Biological Half-Life

    The mean elimination half-life is approximately 25 days.

    5.8 Mechanism of Action

    Although the precise mechanism(s) of action of clofazimine have not been elucidated, its antimicrobial activity appears to be membrane-directed. It was previously thought that, due to its lipophilicity, clofazimine participated in the generation of intracellular reactive oxygen species (ROS) via redox cycling, specifically H2O2 and superoxide, which then exerted an antimicrobial effect. A more recent and compelling theory involves clofazimine interacting with bacterial membrane phospholipids to generate antimicrobial lysophospholipids - bactericidal efficacy may, then, arise from the combined membrane-destabilizing effects of both clofazimine and lysophospholipids, which interfere with K+ uptake and, ultimately, ATP production. The anti-inflammatory activity of clofazimine is the result of its inhibition of T-lymphocyte activation and proliferation. Several mechanisms have been proposed, including direct antagonism of T-cell Kv 1.3 potassium channels and indirect action by promoting the release of E-series prostaglandins and reactive oxygen species from bystander neutrophils and monocytes.

    EU WC

    read-more
    read-more

    01

    Sangrose Laboratories

    India
    American Pharma Summit
    Not Confirmed
    arrow

    Sangrose Laboratories

    India
    arrow
    American Pharma Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Clofazimine (Ph.Eur)

    Date of Issue : 2020-07-17

    Valid Till : 2023-04-27

    Written Confirmation Number : WC-0260

    Address of the Firm : Building no. TP v/714 industrial Estate, Mavelikkara 690570 Kerela

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1715797800,"product":"PHARMACEUTICAL RAW MATERIAL ( BULK DRUGS) : CLOFAZIMINE EP","address":"KAMALA BHUVAN NO.2, 1ST FLR. NO.37","city":"BOMBAY ,MAHARASHTRA","supplier":"TRICON ENTERPRISES PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"BANGKOK","customer":"TO THE ORDER OF","customerCountry":"THAILAND","quantity":"20.00","actualQuantity":"20","unit":"KGS","unitRateFc":"640","totalValueFC":"12659.4","currency":"USD","unitRateINR":52760.75,"date":"16-May-2024","totalValueINR":"1055215","totalValueInUsd":"12659.4","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"9913163","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"THAILAND","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"KAMALA BHUVAN NO.2, 1ST FLR. NO.37, BOMBAY ,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1726857000,"product":"DRUGS AND PHARMACEUTICALS HARMLESSMEDICINES CLOFAZIMINE USP+IN-HOUSE)","address":"304,ATLANTA ARCADE,","city":"MUMBAI MAHARASHTRA","supplier":"MACLEODS PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"SANTA CRUZ PA","customer":"BRMAC COMERCIAL IMPORTADORA DE MAT","customerCountry":"BRAZIL","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"2200","totalValueFC":"6508","currency":"USD","unitRateINR":181791.96333333335,"date":"21-Sep-2024","totalValueINR":"545375.89","totalValueInUsd":"6508","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"4226193","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"304,ATLANTA ARCADE,, MUMBAI MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1727634600,"product":"PHARMACEUTICAL RAW MATERIAL ( BULK DRUGS) CLOFAZIMINE EP","address":"KAMALA BHUVAN NO.2, 1ST FLR. NO.37","city":"BOMBAY ,MAHARASHTRA","supplier":"TRICON ENTERPRISES PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"BANGKOK","customer":"TO THE ORDER OF","customerCountry":"THAILAND","quantity":"20.00","actualQuantity":"20","unit":"KGS","unitRateFc":"640","totalValueFC":"12637.6","currency":"USD","unitRateINR":52952.375,"date":"30-Sep-2024","totalValueINR":"1059047.5","totalValueInUsd":"12637.6","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"4481608","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"THAILAND","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"KAMALA BHUVAN NO.2, 1ST FLR. NO.37, BOMBAY ,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1729449000,"product":"CLOFAZIMINE PH.EUR(B.NO:CL24I034S0)","address":"INDUSTRIAL ESTATE, KOLLAKADAVU","city":"MAVELIKARA, KERALA","supplier":"SANGROSE LABORATORIES","supplierCountry":"INDIA","foreign_port":"HAMBURG - FUHLSBUETT","customer":"HOOPER PHARM GMBH","customerCountry":"GERMANY","quantity":"32.00","actualQuantity":"32","unit":"KGS","unitRateFc":"550","totalValueFC":"17198.6","currency":"USD","unitRateINR":45160.621874999997,"date":"21-Oct-2024","totalValueINR":"1445139.9","totalValueInUsd":"17198.6","indian_port":"Cochin Air","hs_no":"29420090","bill_no":"4986788","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"Cochin Air","supplierAddress":"INDUSTRIAL ESTATE, KOLLAKADAVU, MAVELIKARA, KERALA","customerAddress":""}]
    16-May-2024
    21-Oct-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    MannKind Receives PMDA Clearance for Phase 3 Trial of Clofazimine in NTM Lung Disease

    Details:

    MNKD-101 (clofazimine) is active against both slowly growing and rapidly growing mycobacteria and most Gram-positive bacteria in vitro, being developed for pulmonary nontuberculous mycobacteria.


    Lead Product(s): Clofazimine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: MNKD-101

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 18, 2024

    blank

    01

    Mannkind

    U.S.A
    arrow
    euroPLX 86 Munich
    Not Confirmed

    Mannkind

    U.S.A
    arrow
    euroPLX 86 Munich
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clofazimine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    MannKind Receives PMDA Clearance for Phase 3 Trial of Clofazimine in NTM Lung Disease

    Details : MNKD-101 (clofazimine) is active against both slowly growing and rapidly growing mycobacteria and most Gram-positive bacteria in vitro, being developed for pulmonary nontuberculous mycobacteria.

    Brand Name : MNKD-101

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 18, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    MannKind Receives Fast Track Designation for Clofazimine Inhalation for NTM Lung Disease

    Details:

    MNKD-101 (clofazimine) has antimicrobial and anti-inflammatory effects, active against mycobacteria and Gram-positive bacteria, and is being developed for pulmonary nontuberculous mycobacteria.


    Lead Product(s): Clofazimine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: MNKD-101

    Study Phase: Phase IIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 06, 2024

    blank

    02

    Mannkind

    U.S.A
    arrow
    euroPLX 86 Munich
    Not Confirmed

    Mannkind

    U.S.A
    arrow
    euroPLX 86 Munich
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clofazimine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    MannKind Receives Fast Track Designation for Clofazimine Inhalation for NTM Lung Disease

    Details : MNKD-101 (clofazimine) has antimicrobial and anti-inflammatory effects, active against mycobacteria and Gram-positive bacteria, and is being developed for pulmonary nontuberculous mycobacteria.

    Brand Name : MNKD-101

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    May 06, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    MannKind Announces IND Clearance for Phase 3 Study of Clofazimine Inhalation

    Details:

    MNKD-101 (clofazimine) has antimicrobial and anti-inflammatory effects, active against mycobacteria and Gram-positive bacteria, and is being developed for pulmonary nontuberculous mycobacteria.


    Lead Product(s): Clofazimine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: MNKD-101

    Study Phase: Phase IIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 29, 2024

    blank

    03

    Mannkind

    U.S.A
    arrow
    euroPLX 86 Munich
    Not Confirmed

    Mannkind

    U.S.A
    arrow
    euroPLX 86 Munich
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clofazimine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    MannKind Announces IND Clearance for Phase 3 Study of Clofazimine Inhalation

    Details : MNKD-101 (clofazimine) has antimicrobial and anti-inflammatory effects, active against mycobacteria and Gram-positive bacteria, and is being developed for pulmonary nontuberculous mycobacteria.

    Brand Name : MNKD-101

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    April 29, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RedHill Provides R&D Update

    Details:

    RHB-204 (clarithromycin) is a 70s Bacterial ribosome inhibitor combination of clarithromycin, rifabutin, and clofazimine, developed for the treatment of pulmonary NTM disease caused by Mycobacterium avium Complex (MAC).


    Lead Product(s): Clarithromycin,Rifabutin,Clofazimine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: RHB-204

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 22, 2023

    blank

    04

    RedHill Biopharma

    Israel
    arrow
    euroPLX 86 Munich
    Not Confirmed

    RedHill Biopharma

    Israel
    arrow
    euroPLX 86 Munich
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clarithromycin,Rifabutin,Clofazimine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    RedHill Provides R&D Update

    Details : RHB-204 (clarithromycin) is a 70s Bacterial ribosome inhibitor combination of clarithromycin, rifabutin, and clofazimine, developed for the treatment of pulmonary NTM disease caused by Mycobacterium avium Complex (MAC).

    Brand Name : RHB-204

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    May 22, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering

    Details:

    The Company intends to use the net proceeds for the development of RHB-204, a proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin, and clofazimine, developed for the treatment of pulmonary NTM disease caused by MAC.


    Lead Product(s): Clarithromycin,Rifabutin,Clofazimine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: RHB-204

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: H.C. Wainwright & Co.

    Deal Size: $6.0 million Upfront Cash: Undisclosed

    Deal Type: Public Offering April 03, 2023

    blank

    05

    RedHill Biopharma

    Israel
    arrow
    euroPLX 86 Munich
    Not Confirmed

    RedHill Biopharma

    Israel
    arrow
    euroPLX 86 Munich
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clarithromycin,Rifabutin,Clofazimine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : H.C. Wainwright & Co.

    Deal Size : $6.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering

    Details : The Company intends to use the net proceeds for the development of RHB-204, a proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin, and clofazimine, developed for the treatment of pulmonary NTM disease caused by MAC.

    Brand Name : RHB-204

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    April 03, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RedHill Biopharma Announces $6 Million Registered Direct Offering

    Details:

    The net proceeds will be used in the development of RHB-204, a proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin, and clofazimine, developed for the treatment of pulmonary NTM disease caused by Mycobacterium avium Complex (MAC).


    Lead Product(s): Clarithromycin,Rifabutin,Clofazimine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: RHB-204

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: H.C. Wainwright & Co.

    Deal Size: $6.0 million Upfront Cash: Undisclosed

    Deal Type: Public Offering March 30, 2023

    blank

    06

    RedHill Biopharma

    Israel
    arrow
    euroPLX 86 Munich
    Not Confirmed

    RedHill Biopharma

    Israel
    arrow
    euroPLX 86 Munich
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clarithromycin,Rifabutin,Clofazimine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : H.C. Wainwright & Co.

    Deal Size : $6.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    RedHill Biopharma Announces $6 Million Registered Direct Offering

    Details : The net proceeds will be used in the development of RHB-204, a proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin, and clofazimine, developed for the treatment of pulmonary NTM disease caused by Mycobacterium avium...

    Brand Name : RHB-204

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    March 30, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single Investor

    Details:

    RHB-204 (clarithromycin) is a proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin, and clofazimine, developed for the treatment of pulmonary NTM disease caused by Mycobacterium avium Complex (MAC).


    Lead Product(s): Clarithromycin,Rifabutin,Clofazimine

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RHB-204

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Undisclosed

    Deal Size: $6.0 million Upfront Cash: Undisclosed

    Deal Type: Private Placement March 08, 2023

    blank

    07

    RedHill Biopharma

    Israel
    arrow
    euroPLX 86 Munich
    Not Confirmed

    RedHill Biopharma

    Israel
    arrow
    euroPLX 86 Munich
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clarithromycin,Rifabutin,Clofazimine

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : $6.0 million

    Deal Type : Private Placement

    DEALS_DEV arrow-down

    RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Sin...

    Details : RHB-204 (clarithromycin) is a proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin, and clofazimine, developed for the treatment of pulmonary NTM disease caused by Mycobacterium avium Complex (MAC).

    Brand Name : RHB-204

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    March 08, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease

    Details:

    RHB-204 is a Phase 3-stage proprietary, xed-dose oral capsule containing a combination of clarithromycin, rifabutin and clofazimine, developed for the treatment of pulmonary NTM disease caused by MAC.


    Lead Product(s): Clarithromycin,Rifabutin,Clofazimine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: RHB-204

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 26, 2023

    blank

    08

    RedHill Biopharma

    Israel
    arrow
    euroPLX 86 Munich
    Not Confirmed

    RedHill Biopharma

    Israel
    arrow
    euroPLX 86 Munich
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clarithromycin,Rifabutin,Clofazimine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Tre...

    Details : RHB-204 is a Phase 3-stage proprietary, xed-dose oral capsule containing a combination of clarithromycin, rifabutin and clofazimine, developed for the treatment of pulmonary NTM disease caused by MAC.

    Brand Name : RHB-204

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    January 26, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease

    Details:

    MNKD-101 (clofazimine) possesses antimicrobial and anti-inflammatory properties. It is active against both slowly growing and rapidly growing mycobacteria and most Gram-positive bacteria in vitro. It is currently being developemnt for pulmonary nontuberculous mycobacteria.


    Lead Product(s): Clofazimine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: MNKD-101

    Study Phase: Phase II/ Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 23, 2023

    blank

    09

    Mannkind

    U.S.A
    arrow
    euroPLX 86 Munich
    Not Confirmed

    Mannkind

    U.S.A
    arrow
    euroPLX 86 Munich
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clofazimine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II/ Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatme...

    Details : MNKD-101 (clofazimine) possesses antimicrobial and anti-inflammatory properties. It is active against both slowly growing and rapidly growing mycobacteria and most Gram-positive bacteria in vitro. It is currently being developemnt for pulmonary nontuberc...

    Brand Name : MNKD-101

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    January 23, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine

    Details:

    During the MAD portion of the study, 16 adults were enrolled in one of two cohorts (n = 8 per cohort) that received a daily inhaled dose of 30 mg or 90 mg MNKD-101 (clofazimine) for a seven-day period.


    Lead Product(s): Clofazimine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: MNKD-101

    Study Phase: Phase IProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 06, 2022

    blank

    10

    Mannkind

    U.S.A
    arrow
    euroPLX 86 Munich
    Not Confirmed

    Mannkind

    U.S.A
    arrow
    euroPLX 86 Munich
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clofazimine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine

    Details : During the MAD portion of the study, 16 adults were enrolled in one of two cohorts (n = 8 per cohort) that received a daily inhaled dose of 30 mg or 90 mg MNKD-101 (clofazimine) for a seven-day period.

    Brand Name : MNKD-101

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 06, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    INTERMEDIATES SUPPLIERS

    read-more
    read-more

    01

    Wavelength Pharmaceuticals

    Gabon
    American Pharma Summit
    Not Confirmed
    arrow

    Wavelength Pharmaceuticals

    Gabon
    American Pharma Summit
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    N-(4-Chlorophenyl)-1,2-benzenediamine

    CAS Number : 68817-71-0

    End Use API : Clofazimine

    About The Company : Alchem Phytochemicals APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA inspected// EU GMP certified...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Market Place

    Do you need sourcing support? Ask us

    APIs

    read-more
    read-more
    Brazil.png
    Clofazimine (500 g) API needed in Brazil [ENA14160]
    A government laboratory that focuses in development, production and commercialization of medicines is looking for suppliers of Clofazimine (500 g) API for development purpose. The suppliers must support this enquiry with CoA.
    30 Jun 2022

    Reply

    30 Jun 2022

    Reply text-arrow

    Reply Comment (7)

    30 Jun 2022

    india-flag.png
    Clofazimine (100 g) API needed in India [ENA09162]
    A leading manufacturer and supplier of pharmaceutical products like reference standards, working standards, impurity standards & research chemicals is looking for suppliers of Clofazimine (100 g) API for impurity synthesis.
    30 Nov 2020

    Reply

    30 Nov 2020

    Reply text-arrow

    Reply Comment (4)

    30 Nov 2020

    india-flag.png
    Clofazimine (10 kg) API needed in India [ENA08425]
    A pharmaceutical company that manufactures 2,000 brands in a month which includes dermatology, orthopedics, cardiology, nutraceutical products & digestive enzymes is looking for suppliers of Clofazimine (10 kg) API.
    02 Sep 2020

    Reply

    02 Sep 2020

    Reply text-arrow

    Reply Comment (6)

    02 Sep 2020

    india-flag.png
    IP grade Clofazimine API needed in India [ENA05902]
    A chemistry research group with the objective to develop and produce small to medium volume, complex new chemical entities, generic active pharmaceutical ingredients & their intermediates is looking for suppliers of IP grade Clofazimine API. The quantity required is 50 kg every alternate month.
    29 Nov 2019

    Reply

    29 Nov 2019

    Reply text-arrow

    Reply Comment (4)

    29 Nov 2019

    india-flag.png
    Clofazimine (1 Kg) API needed in India [ENA05611]
    A company with its main focus in manufacturing and development of pharmaceutical formulations is looking for suppliers of Clofazimine (1 Kg) API.
    30 Oct 2019

    Reply

    30 Oct 2019

    Reply text-arrow

    Reply Comment (2)

    30 Oct 2019

    india-flag.png
    Clofazimine API (25 kg) needed in India [ENA03995]
    An Indian company involved in oncology, asthmatic, diabetic and cardiac segmentation is looking for suppliers of Clofazimine API (25 kg).
    23 Apr 2019

    Reply

    23 Apr 2019

    Reply text-arrow

    Reply Comment (1)

    23 Apr 2019

    China.png
    Pramipexole Dihydrochloride, Oseltamivir Phosphate and other APIs needed in China [ENA02641]
    A Chinese company specialized in the research and development of chemically modified drugs and generic drugs is looking for API manufactures for below products who are interest in China market: 1. Pramipexole Dihydrochloride 2. Oseltamivir Phosphate 3. Pregabalin 4. Acarbose 5. Clopidogrel 6. Clofazimine
    15 Nov 2018

    Reply

    15 Nov 2018

    Reply text-arrow

    Reply Comment (2)

    15 Nov 2018

    Market Place
    Enquiry// Clofazimine API needed in the United States [ENA01246]
    A privately held company in the United States is looking for suppliers of Clofazimine API with USDMF for domestic consumption.
    28 Jul 2018

    Reply

    28 Jul 2018

    Reply text-arrow

    Reply Comment (1)

    28 Jul 2018

    Market Place
    Enquiry// Clofazimine API 1-2 kg needed in the United States [ENA00335]
    A government funded research group in the United States is searching for suppliers of Clofazimine API 1-2 kg for research and development. The quantity can be increased after positive outcomes. The API must be from US-FDA approved facility. Interested suppliers should contact Ashok K. Dhawan via Email: dhawanashok@hotmail.com or Tel: 91-9354760523.
    22 May 2017

    Reply

    22 May 2017

    Reply text-arrow

    Reply Comment (0)

    22 May 2017

    PharmaCompass
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF DOSSIERS

    read-more
    read-more
    india-flag.png
    Clofazimine (100 mg) Capsules needed in India [ENA11608]
    The Foundation for Medical Research, an NGO based in India is looking for suppliers of Clofazimine (100 mg) Capsules for commercial purpose. The required quantity is 51,000 units. Interested suppliers can contact them via their email: anjuwakade11@gmail.com.
    11 Oct 2021

    Reply

    11 Oct 2021

    Reply text-arrow

    Reply Comment (2)

    11 Oct 2021

    Russia-big.png
    Various Finished Dosage Formulations needed in Russia [ENA09745]
    A modern Russian diversified pharmaceutical company focused on the development, registration and promotion of original drugs, dietary supplements and medical products is looking for suppliers of Various Finished Dosage Formulations for tender purposes. The suppliers must support this enquiry with European Pharmaceutical Product Certificate or European registration certificate or European free-sale certificate, GMP & CoA. 1. Clofazimine (100 mg) Capsules. The required quantity is 2,44,500 units. 2. Lomustin (40 mg) Capsules. The required quantity is 3,860 units. 3. Procarbazine (50 mg) Capsules. The required quantity is 17,400 units. 4. Antithymocyte Immunoglobulin (50 mg/ ml) Injections. The required quantity is 360 units. 5. Tenofovir (300 mg) Tablets. The required quantity is 1,71,900 units. 6. Azathioprine (50 mg) Tablets. The required quantity is 11,63,500 units. 7. Baclofen (2 mg/ ml in 20 ml) Solution for Intrathecal Administration. The required quantity is 75 units.
    16 Feb 2021

    Reply

    16 Feb 2021

    Reply text-arrow

    Reply Comment (5)

    16 Feb 2021

    Market Place
    Clofazimine (100 mg) capsules needed in China [ENA04797]
    One of the leading distributors focusing on introducing RLD and APIs to the Chinese market is looking for suppliers of RLD of Clofazimine capsules (100 mg). The required volume forecast will be in 3 batches mentioned below: 1. First Batch - 14 Bottles 2. Second Batch - 3 Bottles 3. Third Batch - 3 Bottles.
    01 Aug 2019

    Reply

    01 Aug 2019

    Reply text-arrow

    Reply Comment (1)

    01 Aug 2019

    Ukraine.png
    Clofazimine capsule CTD dossier needed in Ukraine [ENA04585]
    The producer of pharmaceutical/biotechnology/oncology products is looking for suppliers of Clofazimine capsule CTD dossier.
    09 Jul 2019

    Reply

    09 Jul 2019

    Reply text-arrow

    Reply Comment (8)

    09 Jul 2019

    Market Place
    Enquiry//Various Finished Formulations Needed for Sri Lanka [ENA00002]
    Unicorn International Ltd., a leading marketing company in Sri Lanka is searching for manufacturers who can supply 100,000 tablets/injections of the following - 1)Voriconazole 200mg tablets 2) Voriconazole 200mg injection 3) Diazepam tablet 2mg/ 5mg /10mg 4) Diazepam injections 10mg/2ml 5) Dapsone 50mg /100mg tablets 6) Bortezomib 2mg injection 7) Rituximab 500mg / 50 ml 8) Clofazimine 100mg Interested companies should contact Thanuj Fernando M.D (M. A.) CEO/ Director Unicorn International Pvt Ltd No.207,Lion City , Liyangemulla , Seeduwa , Sri Lanka Tel : 0094 710387600 Fax : 0094 711001209 Mob : 0094 772387600 Web Site : http://www.unicornintl.com
    25 Mar 2016

    Reply

    25 Mar 2016

    Reply text-arrow

    Reply Comment (1)

    25 Mar 2016

    PharmaCompass
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    USP

    read-more
    read-more

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search